Fermion-Header

Fermion-Header

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

Intas Pharmaceuticals

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SupplySide West 2021

Participation Not Confirmed

Update your Virtual Booth

Naari Completes Acquisition of ANDAs from Intas Pharmaceuticals

Lead Product(s): Undisclosed

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Undisclosed

Partner/Sponsor/Collaborator: Naari

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 10, 2020

Details:

The portfolio acquired comprises eight U.S. FDA approved ANDAs and two products pending approval. It includes generic products in female hormones which will be manufactured at Naari’s dedicated female hormone facility in India and commercialized over the next 24 months.